Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Turkey study reveals hidden fatty liver burden in overweight adults

NCT ID NCT07548970

Knowledge-focused Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how common Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is among 459 adults in Turkey who are at risk due to being overweight, having diabetes, or other metabolic issues. Researchers used a special ultrasound to measure liver fat and stiffness, and collected information on diet, activity, and blood markers. The goal was to find undiagnosed cases and understand what factors are linked to the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

459 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

459 male and female participants aged between 18-80, who can sign the informed consent and are eligible to participate.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: One of the following conditions: * BMI ≥ 25 kg/m2 OR WC\> 94 cm (M) 80 cm (F) * Fasting serum glucose ≥ 100 mg/dL OR 2-hour post-load glucose levels ≥140 mg/dL OR HbA1c ≥ 5.7% OR type 2 diabetes OR treatment for type 2 diabetes * Blood pressure ≥ 130/85 mmHg OR specific antihypertensive drug treatment * Plasma triglycerides ≥ 150 mg/dL OR lipid lowering treatment * Plasma HDL-cholesterol ≤40 mg/dL (Male) and ≤ 50 mg/dL (Female) OR lipid lowering treatment Exclusion Criteria: * Excessive alcohol use (more than 20 g/day for women and 30g/day for men= \>2 glasses alcohol/day for women and \>3 glasses for men) * Hepatitis B virus, * Hepatitis C virus, * Autoimmune hepatitis, * Primary biliary cirrhosis, * Hemochromatosis, * Wilson's disease, * Alpha 1 antitrypsin deficiency * HCV Genotype 3, * Total parental nutrition, * Current use of hepatotoxic medications (amiodarone, tamoxifen, methotrexate, corticosteroids and HAART), * Celiac disease, * Pregnancy and breastfeeding * A history of bariatric surgery * Current diagnosis of liver cirrhosis and/or hepatocellular carcinoma. * Current diagnosis of extrahepatic malignancy(s) or prior diagnosis within last 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ferritin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperuricemia metabolic dysfunction-associated steatotic liver disease Motor Activity Sedentary Behavior vitamin D deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ferritin Hyperuricemia and mafld Lifestyle (sedentary behavior and physical activity) Masld (metabolic dysfunction-associated steatotic liver disease) Mediterranean diet Vitamin D deficiency

Contacts and locations

Locations

  • Temel Tıp Bilimleri

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.